

Roberto Ferrari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8161050/roberto-ferrari-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

503
papers

45,675
citations

79
h-index

207
g-index

541
ext. papers

52,774
ext. citations

6.2
avg, IF

6.87
L-index

#	Paper	IF	Citations
503	INTERventional treatment for CARDIovaScular life-threatening diseases (Why is the INTERCARDIS an important project for the cardiological community?): strategies for improving patient outcome and hospital costs.. <i>European Heart Journal Supplements</i> , 2022 , 24, B1	1.5	
502	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.. <i>European Journal of Preventive Cardiology</i> , 2022 , 28, 1795-1806	3.9	0
501	Similarities between fibroblasts and cardiomyocytes in the study of the permeability transition pore.. <i>European Journal of Clinical Investigation</i> , 2022 , e13764	4.6	0
500	Renin-Angiotensin-Aldosterone System Inhibitors, Statins, and Beta-Blockers in Diabetic Patients With Critical Limb Ischemia and Foot Lesions.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022 , 27, 10742484221101980	2.6	
499	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	4
498	CoronaPversus CoronaryP. <i>European Heart Journal</i> , 2021 , 42, 555-557	9.5	1
497	Phenotypic heterogeneity of COVID-19 pneumonia: clinical and pathophysiological relevance of the vascular phenotype. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
496	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. <i>Platelets</i> , 2021 , 32, 560-567	3.6	14
495	Time course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study. <i>Clinical and Translational Medicine</i> , 2021 , 11, e283	5.7	15
494	A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients. <i>Cell Reports</i> , 2021 , 35, 108983	10.6	11
493	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
492	Standard ECG in Brugada Syndrome as a Marker of Prognosis: From Risk Stratification to Pathophysiological Insights. <i>Journal of the American Heart Association</i> , 2021 , 10, e020767	6	5
491	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021 , 89, 65-75	3.9	2
490	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). <i>American Journal of Cardiology</i> , 2021 , 150, 40-46	3	1
489	The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 Pneumonia. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
488	The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good. <i>Current Problems in Cardiology</i> , 2021 , 46, 100554	17.1	5
487	Left ventricular output indices in hospitalized heart failure: when "simpler" may not mean "better". <i>International Journal of Cardiovascular Imaging</i> , 2021 , 37, 59-68	2.5	1

486	Diastolic dysfunction, frailty and prognosis in elderly patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2021 , 327, 31-35	3.2	1
485	Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. <i>Clinical Cardiology</i> , 2021 , 44, 58-65	3.3	1
484	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 28-33	4.6	1
483	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 287-294	4.6	1
482	Myocarditis in COVID-19 patients: current problems. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1123-1129	3.9	29
481	Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. <i>Critical Care</i> , 2021 , 25, 74	10.8	38
480	Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape. <i>Biomedicines</i> , 2021 , 9,	4.8	7
479	Impairment of mitophagy and autophagy accompanies calcific aortic valve stenosis favoring cell death and the severity of disease. <i>Cardiovascular Research</i> , 2021 ,	9.9	8
478	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021 , 144, 512-523	16.7	6
477	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. <i>European Journal of Internal Medicine</i> , 2021 , 90, 10-15	3.9	1
476	Adding a "Notch" to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 695114	5.7	7
475	Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
474	Novel Echocardiographic Approach to Hemodynamic Phenotypes Predicts Outcome of Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Imaging</i> , 2020 , 13, e009939	3.9	9
473	The Black Death and the physician at the time of COVID-19. <i>European Heart Journal</i> , 2020 , 41, 3501-3502	3.5	2
472	Paradoxical low-flow phenotype in hospitalized heart failure with preserved ejection fraction. <i>IJC Heart and Vasculature</i> , 2020 , 28, 100539	2.4	1
471	Response by Mele et al to Letter Regarding Article, "Novel Echocardiographic Approach to Hemodynamic Phenotypes Predicts Outcome of Patients Hospitalized With Heart Failure". <i>Circulation: Cardiovascular Imaging</i> , 2020 , 13, e011045	3.9	1
470	Lamin A/C Missense Mutation R216C Pinpoints Overlapping Features Between Brugada Syndrome and Laminopathies. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e002751	5.2	1
469	2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 331-332	6.4	2

468	Reply to the new ESC guidelines for the diagnosis and management of chronic coronary syndromes: Can we use them in practice?. <i>International Journal of Cardiology</i> , 2020 , 305, 42	3.2	
467	Understanding the results of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 1531-1535	6	
466	Ticagrelor Increases and mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
465	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1495-1503	12.3	56
464	COVID-19 testing. <i>European Heart Journal</i> , 2020 , 41, 2427-2428	9.5	2
463	The battle against COVID-19: mortality in Italy. <i>European Heart Journal</i> , 2020 , 41, 2050-2052	9.5	17
462	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320918728	3.9	8
461	Living with stable angina: patients pathway and needs in angina. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 377-382	1.9	1
460	The Cardiologist at the time of Coronavirus: a perfect storm. <i>European Heart Journal</i> , 2020 , 41, 1320-1325	9.5	3
459	Priorities for Cath labs in the COVID-19 tsunami. <i>European Heart Journal</i> , 2020 , 41, 1784-1785	9.5	7
458	Key words to be adopted for COVID-19 research. <i>European Heart Journal</i> , 2020 , 41, 4229-4230	9.5	2
457	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 92-102	12.3	35
456	Echocardiographic Evaluation of Left Ventricular Output in Patients with Heart Failure: A Per-Beat or Per-Minute Approach?. <i>Journal of the American Society of Echocardiography</i> , 2020 , 33, 135-147.e3	5.8	16
455	The journey of omega-3 fatty acids in cardiovascular medicine. <i>European Heart Journal Supplements</i> , 2020 , 22, J49-J53	1.5	2
454	Current Role of Echocardiography in Cardiac Resynchronization Therapy: from Cardiac Mechanics to Flow Dynamics Analysis. <i>Current Heart Failure Reports</i> , 2020 , 17, 384-396	2.8	3
453	Aortic Valve Stenosis and Mitochondrial Dysfunctions: Clinical and Molecular Perspectives. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
452	What Happened to Electrocardiogram as a Screening Test to Recognize Cardiovascular Complications in COVID-19 Patients?. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2799-2800 ^{15.1}		
451	COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5

450	Right Atrial Pressure Is Associated with Outcomes in Patients with Heart Failure and Indeterminate Left Ventricular Filling Pressure. <i>Journal of the American Society of Echocardiography</i> , 2020 , 33, 1345-1356	5.8	6
449	Adapting to survive. <i>European Heart Journal</i> , 2020 , 41, 3981-3983	9.5	
448	Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement. <i>Europace</i> , 2020 , 22, 1848-1854	3.9	36
447	Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2020 , 396, 830-838	4.0	23
446	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020 , 75, 1113-1119	6.4	31
445	ARNIs: balancing "the good and the bad" of neuroendocrine response to HF. <i>Clinical Research in Cardiology</i> , 2020 , 109, 599-610	6.1	3
444	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 426-436	3.9	9
443	Nutritional status and all-cause mortality in older adults with acute coronary syndrome. <i>Clinical Nutrition</i> , 2020 , 39, 1572-1579	5.9	15
442	From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. <i>Heart Failure Reviews</i> , 2020 , 25, 217-230	5	12
441	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020 , 41, 347-356	9.5	20
440	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 804-812	12.3	4
439	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320912491	3.9	1
438	Intracardiac flow analysis in cardiac resynchronization therapy: A new challenge?. <i>Echocardiography</i> , 2019 , 36, 1919-1929	1.5	5
437	A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019 , 210, 98-107	4.9	7
436	Prognosis after pacemaker implantation in extreme elderly. <i>European Journal of Internal Medicine</i> , 2019 , 65, 37-43	3.9	4
435	New onset of chest pain: the importance of remote monitoring. <i>European Heart Journal Supplements</i> , 2019 , 21, C32-C36	1.5	
434	Understanding ARNIs. <i>European Heart Journal</i> , 2019 , 40, 1397-1398	9.5	2
433	The multifaceted angina. <i>European Heart Journal Supplements</i> , 2019 , 21, C1-C5	1.5	2

432	Angina and chronic obstructive pulmonary disease: facing the perfect storm. <i>European Heart Journal Supplements</i> , 2019 , 21, C17-C20	1.5	1
431	Angina and left ventricular dysfunction: can we ReduceIt?. <i>European Heart Journal Supplements</i> , 2019 , 21, C28-C31	1.5	
430	Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. <i>Frontiers in Physiology</i> , 2019 , 10, 217	4.6	5
429	Living alone and cardiovascular disease outcomes. <i>Heart</i> , 2019 , 105, 1087-1095	5.1	10
428	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. <i>Drugs</i> , 2019 , 79, 1543-1556	12.1	7
427	Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019 , 16, 284-291	2	2
426	The Notch pathway: a novel therapeutic target for cardiovascular diseases?. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 695-710	6.4	13
425	KRIT1 Deficiency Promotes Aortic Endothelial Dysfunction. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
424	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	4
423	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1362-1364	15.1	27
422	Exosome in Cardiovascular Diseases: A Complex World Full of Hope. <i>Cells</i> , 2019 , 8,	7.9	69
421	Treating angina. <i>European Heart Journal Supplements</i> , 2019 , 21, G1-G3	1.5	0
420	Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. <i>European Heart Journal</i> , 2019 , 40, 190-194	9.5	31
419	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. <i>European Heart Journal</i> , 2019 , 40, 1399-1407	9.5	35
418	CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis. <i>Clinical Cardiology</i> , 2019 , 42, 358-364	3.3	8
417	Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis. <i>Heart</i> , 2019 , 105, 834-841	5.1	43
416	Intracardiac Flow Analysis: Techniques and Potential Clinical Applications. <i>Journal of the American Society of Echocardiography</i> , 2019 , 32, 319-332	5.8	31
415	Anti-anginal drugs: Systematic review and clinical implications. <i>International Journal of Cardiology</i> , 2019 , 283, 55-63	3.2	13

414	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018 , 20, 842-850	12.3	13
413	The Impact of Surgical and Trans-Catheter Aortic Valve Replacement on Endothelial Function: New Markers Ahead 2018 , 359-366		
412	Major unmet needs in the cardiovascular area. <i>European Heart Journal Supplements</i> , 2018 , 20, C4-C7	1.5	
411	Ferrara IV. <i>European Heart Journal</i> , 2018 , 39, 497-501	9.5	3
410	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006023	6	51
409	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 377-387	3.9	8
408	Beyond cardiomyocyte loss: Role of Notch in cardiac aging. <i>Journal of Cellular Physiology</i> , 2018 , 233, 5670-5683		4
407	Left ventricular ejection fraction and heart failure: an indissoluble marriage?. <i>European Journal of Heart Failure</i> , 2018 , 20, 427-430	12.3	27
406	Echocardiographic evaluation of cardiac dyssynchrony: Does it still matter?. <i>Echocardiography</i> , 2018 , 35, 707-715	1.5	5
405	Ferrara V. <i>European Heart Journal</i> , 2018 , 39, 977-981	9.5	1
404	Role of ivabradine in management of stable angina in patients with different clinical profiles. <i>Open Heart</i> , 2018 , 5, e000725	3	5
403	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. <i>Hypertension</i> , 2018 , 71, 168-176	8.5	30
402	Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 100-110	12.3	49
401	Expert consensus document: A Diamond Approach to personalized treatment of angina. <i>Nature Reviews Cardiology</i> , 2018 , 15, 120-132	14.8	66
400	Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. <i>European Journal of Internal Medicine</i> , 2018 , 47, 82-86	3.9	6
399	Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F/F-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 7131-7143	8.3	31
398	Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF). <i>Frontiers in Physiology</i> , 2018 , 9, 337	4.6	17
397	Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): rationale and design of a randomized clinical trial. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 98	2.3	19

396	New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2018 , 8, 91	5.3	33
395	Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis. <i>Systematic Reviews</i> , 2018 , 7, 131	3	4
394	Are all children born the same?. <i>European Heart Journal</i> , 2018 , 39, 3411-3415	9.5	
393	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. <i>European Heart Journal</i> , 2018 , 39, 3855-3863	9.5	15
392	Treatment of Angina: Where Are We?. <i>Cardiology</i> , 2018 , 140, 52-67	1.6	22
391	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. <i>Cardiology</i> , 2018 , 140, 74-82	1.6	2
390	Full Sternotomy, Hemisternotomy, and Minithoracotomy for Aortic Valve Surgery: Is There a Difference?. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 1782-1788	2.7	14
389	Ferrara III. <i>European Heart Journal</i> , 2018 , 39, 88-90	9.5	2
388	Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. <i>American Journal of Medicine</i> , 2017 , 130, 720-730	2.4	29
387	Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. <i>Chronic Respiratory Disease</i> , 2017 , 14, 117-126	3	31
386	Noninvasive evaluation of right hemodynamics in carcinoid heart disease: A case report. <i>Journal of Clinical Ultrasound</i> , 2017 , 45, 355-361	1	
385	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. <i>Diabetes Care</i> , 2017 , 40, 671-678	14.6	65
384	Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome. <i>Cardiology</i> , 2017 , 137, 256-260	1.6	14
383	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1242-1254	12.3	166
382	A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics. <i>Cardiology</i> , 2017 , 138, 69-72	1.6	1
381	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017 , 244, 59-66	3.2	16
380	Mitochondrial permeability transition involves dissociation of FF ATP synthase dimers and C-ring conformation. <i>EMBO Reports</i> , 2017 , 18, 1077-1089	6.5	122
379	Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017 , 40, 797-806	3.3	29

378	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1574-1585	12.3	301
377	Reperfusion Damage - A Story of Success, Failure, and Hope. <i>Circulation Journal</i> , 2017 , 81, 131-141	2.9	31
376	Ferrara I: Introduction: Why and how do cardiologists need to take an interest and lead prevention programmes?. <i>European Heart Journal</i> , 2017 , 38, 3255-3257	9.5	4
375	Ferrara II. <i>European Heart Journal</i> , 2017 , 38, 3337-3339	9.5	2
374	Extracorporeal Circulatory Support in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2017 , 45, e1173-e1183	1.4	20
373	Estrogen receptor α dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNF)-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2017 , 292, 18178-18191	5.4	36
372	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. <i>Data in Brief</i> , 2017 , 14, 197-205	1.2	10
371	Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 1001-1011	5.8	15
370	Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study. <i>Journal of Translational Medicine</i> , 2017 , 15, 98	8.5	18
369	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 54-65	12.3	92
368	The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rationale and design of a multicenter prospective study. <i>Aging Clinical and Experimental Research</i> , 2017 , 29, 895-903	4.8	16
367	The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction. <i>European Heart Journal</i> , 2017 , 38, 138-139	9.5	2
366	Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1208-1216	7	39
365	Current role of echocardiography in cardiac resynchronization therapy. <i>Heart Failure Reviews</i> , 2017 , 22, 699-722	5	13
364	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0182124	3.7	6
363	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017 , 19, D3-D54	1.5	11
362	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. <i>Polish Archives of Internal Medicine</i> , 2017 , 127, 107-114	1.9	2
361	Uric acid and coronary artery disease: An elusive link deserving further attention. <i>International Journal of Cardiology</i> , 2016 , 213, 28-32	3.2	46

360	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016 , 37, 152-60	9.5	21
359	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016 , 388, 2142-2152	4.0	261
358	PredischARGE screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. <i>International Journal of Cardiology</i> , 2016 , 222, 806-812	3.2	16
357	Cardiac resynchronization therapy guided by multimodality cardiac imaging. <i>European Journal of Heart Failure</i> , 2016 , 18, 1375-1382	12.3	42
356	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study). <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 555-562	2.7	32
355	Current views on anthracycline cardiotoxicity. <i>Heart Failure Reviews</i> , 2016 , 21, 621-34	5	35
354	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. <i>International Journal of Cardiovascular Imaging</i> , 2016 , 32, 211-223	2.5	13
353	International cooperation in healthcare: model of IRCCS Policlinico San Donato and Bambini Cardiopatici nel Mondo Association for congenital heart diseases. <i>European Heart Journal Supplements</i> , 2016 , 18, E72-E78	1.5	6
352	How can the European Society of Cardiology ensure compliance with ethical standards?. <i>European Heart Journal</i> , 2016 , 37, 741-4	9.5	3
351	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. <i>Platelets</i> , 2016 , 27, 484-7	3.6	26
350	Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016 , 34, 813-21	1.9	97
349	Reincarnated medicines: using out-dated drugs for novel indications. <i>European Heart Journal</i> , 2016 , 37, 2571-6	9.5	5
348	Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients. <i>Ultrasound in Medicine and Biology</i> , 2016 , 42, 125-32	3.5	10
347	Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9, 31-8	5.8	11
346	Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 509-14	2	30
345	Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2016 , 17, 668-77	4.1	15
344	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016 , 203, 22-9	3.2	45
343	Remote monitoring of implantable devices: Should we continue to ignore it?. <i>International Journal of Cardiology</i> , 2016 , 202, 368-77	3.2	22

342	Remodelling after an Infarct: Crosstalk between Life and Death. <i>Cardiology</i> , 2016 , 135, 68-76	1.6	3
341	Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings. <i>International Journal of Cardiology</i> , 2016 , 221, 993-7	3.2	19
340	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016 , 18, 613-25	12.3	316
339	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 859-68	12.3	26
338	Can We Improve Myocardial Protection during Ischaemic Injury?. <i>Cardiology</i> , 2016 , 135, 14-26	1.6	9
337	Heart failure: an historical perspective. <i>European Heart Journal Supplements</i> , 2016 , 18, G3-G10	1.5	10
336	Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. <i>BMC Medicine</i> , 2016 , 14, 215	11.4	307
335	Heart rate reduction in coronary artery disease and heart failure. <i>Nature Reviews Cardiology</i> , 2016 , 13, 493-501	14.8	40
334	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016 , 18, C2-C12	1.5	56
333	Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. <i>Journal of the American Heart Association</i> , 2016 , 5, e002688	6	10
332	Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. <i>American Journal of Medicine</i> , 2015 , 128, 1102-1108.e6	2.4	19
331	Enhanced stent visualization systems during PCI: A case series and review of literature. <i>Journal of Cardiology Cases</i> , 2015 , 12, 1-5	0.6	6
330	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbasco-side treatment. A randomized study. <i>Pharmacological Research</i> , 2015 , 97, 1-6	10.2	23
329	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 90-100	3.3	283
328	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. <i>European Heart Journal</i> , 2015 , 36, 3291-6	9.5	31
327	The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. <i>European Heart Journal</i> , 2015 , 36, 2042-2046	9.5	16
326	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , 2015 , 17, 665-71	12.3	97
325	Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 1056-65	3.9	41

324	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015 , 19, 1-12	1.7	50
323	Perindopril and β blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUROPEAN trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. <i>American Heart Journal</i> , 2015 , 170, 1092-8	4.9	13
322	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry. <i>Medicina (Lithuania)</i> , 2015 , 51, 240-6	3.1	6
321	Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015 , 22, 535-41	4	10
320	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015 , 10, e0125164	3.7	9
319	Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker?. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 123-32	7	17
318	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 191, 187-93	3.2	47
317	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. <i>Value in Health</i> , 2015 , 18, 1098-104	3.3	8
316	Ivabradine in the management of coronary artery disease with or without left ventricular dysfunction or heart failure. <i>European Heart Journal Supplements</i> , 2015 , 17, G24-G29	1.5	2
315	The ivabradine journey: Table 1. <i>European Heart Journal Supplements</i> , 2015 , 17, G1-G9	1.5	0
314	Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA. <i>International Journal of Cardiology</i> , 2015 , 182, 194-9	3.2	9
313	Cancer therapy-induced cardiotoxicity: role of ultrasound deformation imaging as an aid to early diagnosis. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 627-43	3.5	23
312	Prevention and Control of Cardiovascular Diseases: Integrated and Complimentary Strategies 2015 , 219-226		
311	Heart rate and use of β blockers in Mexican stable outpatients with coronary artery disease. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 270-7	0.2	5
310	The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors. <i>Frontiers in Oncology</i> , 2014 , 4, 384	5.3	25
309	Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 506-12	15.1	45
308	Alteration of Notch signaling and functionality of adipose tissue derived mesenchymal stem cells in heart failure. <i>International Journal of Cardiology</i> , 2014 , 174, 119-26	3.2	10
307	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 136.e1-136.e56	1.5	8

306	Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1833-41	15.1	99
305	Coronary artery disease: Use of ACE inhibitors in stable CAD--what is the truth?. <i>Nature Reviews Cardiology</i> , 2014 , 11, 315-6	14.8	3
304	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 1091-9	59.2	315
303	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2733-79	9.5	2361
302	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2014	9.5	3467
301	Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. <i>International Journal of Cardiology</i> , 2014 , 176, 119-24	3.2	22
300	The Notch pathway: a novel target for myocardial remodelling therapy?. <i>European Heart Journal</i> , 2014 , 35, 2140-5	9.5	35
299	Management of outpatients in France with stable coronary artery disease. Findings from the prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. <i>Archives of Cardiovascular Diseases</i> , 2014 , 107, 452-61	2.7	9
298	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
297	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 135.e1-135.e81	1.5	9
296	Características demográficas y clínicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 538-544	1.5	13
295	Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. <i>International Journal of Cardiology</i> , 2014 , 173, 343-5	3.2	7
294	Ivabradine: heart rate and left ventricular function. <i>Cardiology</i> , 2014 , 128, 226-30	1.6	10
293	Ivabradine in stable coronary artery disease. <i>New England Journal of Medicine</i> , 2014 , 371, 2435	59.2	11
292	Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. <i>JAMA Internal Medicine</i> , 2014 , 174, 1651-9	11.5	84
291	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. <i>Thorax</i> , 2014 , 69, 80-1	7.3	23
290	In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure. <i>Mediators of Inflammation</i> , 2014 , 2014, 257081	4.3	9
289	Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 612-23	9.5	119

288	Insufficient control of heart rate in stable coronary artery disease patients in Latvia. <i>Medicina (Lithuania)</i> , 2014 , 50, 295-302	3.1	1
287	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European	3	588
286	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , 35, 2383-431	9.5	849
285	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). <i>Cardiovascular Diabetology</i> , 2014 , 13, 102	8.7	153
284	Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. <i>International Journal of Cardiology</i> , 2014 , 177, 711-3	3.2	3
283	Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. <i>PLoS ONE</i> , 2014 , 9, e102335	3.7	18
282	Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 538-44	0.7	2
281	The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 705-17	2.5	35
280	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013 , 167, 296-7	3.2	10
279	The Notch pathway: a crossroad between the life and death of the endothelium. <i>European Heart Journal</i> , 2013 , 34, 2504-9	9.5	37
278	Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). <i>JACC: Cardiovascular Interventions</i> ,	5	74
277	Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. <i>Thrombosis Research</i> , 2013 , 132, 151-7	8.2	18
276	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013 , 34, 3035-87	9.5	1444
275	Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. <i>Respirology</i> , 2013 , 18, 125-30	3.6	24
274	Pacing transmural scar tissue reduces left ventricle reverse remodeling after cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2013 , 167, 94-101	3.2	18
273	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2013 , 167, 2938-43	3.2	48
272	Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. <i>American Heart Journal</i> , 2013 , 166, 654-661.e6	4.9	22
271	Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock. <i>Journal of Cardiology Cases</i> , 2013 , 7, e74-e77	0.6	3

270	Three-year follow-up of the MULTICentre evaluation of Single high-dose Bolus TiRoFiban versus Abciximab with Sirolimus-eluting STent or Bare-Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY). <i>International Journal of Cardiology</i> , 2013 , 165, 134-41	3.2	24
269	Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease. <i>American Journal of Cardiology</i> , 2013 , 112, 27-33	3	23
268	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
267	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013 , 34, 2263-70	9.5	72
266	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 2949-3003	9.5	3076
265	Revising common beliefs in the management of stable CAD. <i>Nature Reviews Cardiology</i> , 2013 , 10, 65-6	14.8	7
264	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). <i>European Heart Journal</i> , 2013 , 34, 909-19	9.5	95
263	RAAS inhibition and mortality in hypertension. <i>Global Cardiology Science & Practice</i> , 2013 , 2013, 269-78	0.7	14
262	The role of Notch pathway in cardiovascular diseases. <i>Global Cardiology Science & Practice</i> , 2013 , 2013, 44	0.7	9
261	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2013 , 34, 2281-329	9.5	1491
260	17Estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells. <i>PLoS ONE</i> , 2013 , 8, e71440	3.7	46
259	In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndrome. <i>PLoS ONE</i> , 2013 , 8, e56377	3.7	25
258	The role of Notch pathway in cardiovascular diseases. <i>Global Cardiology Science & Practice</i> , 2013 , 2013, 364-71	0.7	17
257	RAAS inhibition and mortality in hypertension: from pharmacology to clinical evidence. <i>Kardiologia Polska</i> , 2013 , 71, 1-7	0.9	2
256	Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). <i>European Heart Journal</i> , 2012 , 33, 2910-6	9.5	27
255	The in vitro effects of verbasco-side on human platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 318-25	5.1	17
254	Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). <i>Circulation</i> , 2012 , 126, 2769-75	16.7	83
253	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. <i>American Heart Journal</i> , 2012 , 163, 104-11	4.9	12

252	Pro-inflammatory genetic profile and familiarity of acute myocardial infarction. <i>Immunity and Ageing</i> , 2012 , 9, 14	9.7	16
251	Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of	5	140
250	Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2343-8	15.1	99
249	Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. <i>PLoS ONE</i> , 2012 , 7, e36284	3.7	60
248	Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. <i>British Journal of Pharmacology</i> , 2012 , 165, 1457-66	8.6	47
247	Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 680-7	1	17
246	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012 , 14, 1056-66	12.3	88
245	Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. <i>Circulation</i> , 2012 , 125, 2015-26	16.7	526
244	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , 2012 , 33, 2831-40	9.5	474
243	PERTINENT: AUTHORSPRETROSPECTIVE. <i>Cardiovascular Research</i> , 2012 , 96, 204-207	9.9	2
242	Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. <i>EuroIntervention</i> , 2012 , 8, 71-8	3.1	22
241	Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). <i>Global Heart</i> , 2012 , 7, 297-305	2.9	26
240	Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2474-83	15.1	280
239	ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2011 , 11, 189-98	4	34
238	Genetic determinants of on-clopidogrel high platelet reactivity. <i>Platelets</i> , 2011 , 22, 399-407	3.6	44
237	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. <i>International Journal of Cardiology</i> , 2011 , 146, 408-14	3.2	69
236	Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 959-73	2.5	9
235	Heart rate: a forgotten link in coronary artery disease?. <i>Nature Reviews Cardiology</i> , 2011 , 8, 369-79	14.8	58

234	The Mediterranean diet: a cultural journey. <i>Lancet, The</i> , 2011 , 377, 1730-1	40	10
233	The Mediterranean diet: a cultural journey [AuthorsPreply]. <i>Lancet, The</i> , 2011 , 378, 767	40	
232	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. <i>Journal of Hypertension</i> , 2011 , 29, 509-19	1.9	40
231	Different image integration modalities to guide AF ablation: impact on procedural and fluoroscopy times. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011 , 34, 422-30	1.6	22
230	Circulating stem cell vary with NYHA stage in heart failure patients. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 1726-36	5.6	23
229	Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). <i>American Journal of Cardiology</i> , 2011 , 107, 805-11	3	29
228	Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 531-7	3.9	52
227	Different clinical models of CD34+ cells mobilization in patients with cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 1-8	5.1	12
226	Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial	5	22
225	The heart rate story. <i>European Heart Journal Supplements</i> , 2011 , 13, C4-C13	1.5	8
224	Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H366-73	5.2	42
223	Noncontact mapping of left ventricle during CRT implant. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010 , 33, 74-84	1.6	6
222	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. <i>Journal of Blood Medicine</i> , 2010 , 1, 61-9	2.3	2
221	Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010 , 16, 591-3	3.3	2
220	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010 , 31, 1854-64	9.5	56
219	Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). <i>Journal of the American College of Cardiology</i>	15.1	14
218	Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1447-55	15.1	100
217	Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. <i>American Heart Journal</i> , 2010 , 159, 795-802	4.9	26

216	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). <i>American Heart Journal</i> , 2010 , 160, 804-11	4.9	54
215	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. <i>Atherosclerosis</i> , 2010 , 210, 274-7	3.1	56
214	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. <i>Atherosclerosis</i> , 2010 , 211, 333-6	3.1	25
213	TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. <i>Cellular and Molecular Life Sciences</i> , 2010 , 67, 1307-14	10.3	17
212	Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 331-9	3.9	36
211	Poor response to clopidogrel: current and future options for its management. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 319-31	5.1	47
210	Concerns and hopes for stem cell therapy in cardiology: focus on endothelial progenitor cells. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2010 , 10, 216-23	1.1	5
209	Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. <i>PLoS ONE</i> , 2009 , 4, e4442	3.7	68
208	A modern fairy tale. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S65-7		1
207	The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. <i>European Heart Journal</i> , 2009 , 30, 1385-94	9.5	46
206	Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. <i>European Heart Journal</i> , 2009 , 30, 1656-65	9.5	16
205	Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. <i>European Heart Journal</i> , 2009 , 30, 2337-45	9.5	154
204	Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. <i>Cardiovascular Research</i> , 2009 , 84, 72-82	9.9	32
203	Comparison of myocardial deformation and velocity dyssynchrony for identification of responders to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2009 , 11, 391-9	12.3	22
202	Cardiovascular disease. Preface. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S1		1
201	Temporal and genotype-driven variation of factor VII levels in patients with acute myocardial infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 119-22	3.3	3
200	Radiofrequency ablation of paroxysmal atrial fibrillation by mesh catheter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009 , 25, 135-40	2.4	4
199	Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?. <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 161-70	3.9	22

198	Contact versus noncontact mapping for ablation of ventricular tachycardia in patients with previous myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 842-50	1.6	7
197	Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Clopidogrel study. <i>Circulation</i> , 2009 , 119, 2017-23	16.7	191
196	Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. <i>Archives of Cardiovascular Diseases</i> , 2009 , 102, 89-96	2.7	7
195	The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1900-1	15.1	36
194	Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate EUROPA story. <i>Drugs</i> , 2009 , 69, 265-77	12.1	33
193	Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 345-60	2.5	18
192	ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study. <i>Atherosclerosis</i> , 2009 , 204, 273-5	3.1	18
191	Echocardiographic myocardial scar burden predicts response to cardiac resynchronization therapy in ischemic heart failure. <i>Journal of the American Society of Echocardiography</i> , 2009 , 22, 702-8	5.8	39
190	Cardiovascular protection: a breakthrough for high-risk patients?. <i>Journal of Hypertension</i> , 2009 , 27, S37-40		
189	Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 505-08	1.9	8
188	A step further with ivabradine: SIGNIFY (Study assessINg the morbidity/mortality beNefits of the If inhibitor ivabradine in patients with coronary artery disease). <i>European Heart Journal Supplements</i> , 2009 , 11, D19-D27	1.5	15
187	Mechanisms of remodelling: a question of life (stem cell production) and death (myocyte apoptosis). <i>Circulation Journal</i> , 2009 , 73, 1973-82	2.9	36
186	Neuroendocrine Control of the Cardiovascular System in Heart Failure 2009 , 13-20		
185	Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. <i>Current Medical Research and Opinion</i> , 2008 , 24, 3543-57	2.5	17
184	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. <i>International Journal of Cardiology</i> , 2008 , 128, 53-61	3.2	1
183	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	40	775
182	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , 2008 , 372, 817-21	40	584
181	Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using Doppler measures of myocardial strain. <i>Journal of the American Society of Echocardiography</i> , 2008 , 21, 1257-64	5.8	28

180	Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?. <i>Circulation</i> , 2008 , 117, 136-43	16.7	82
179	Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1788-99	27.4	214
178	Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. <i>Current Opinion in Cardiology</i> , 2008 , 23, 296-301	2.1	10
177	Radiofrequency atrial fibrillation ablation based on pathophysiology: a diversified protocol with long-term follow-up. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 68-75	1.9	6
176	Abciximab: a reappraisal of its use in coronary care. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 29-39	4.4	6
175	Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. <i>Cardiovascular Drugs and Therapy</i> , 2008 , 22, 313-20	3.9	17
174	Paroxysmal atrial fibrillation ablation with the multipolar mapping and ablation catheter (Mesh-Bard). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008 , 31, 753-6	1.6	5
173	Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 1037-46	2.5	17
172	Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. <i>Pharmacological Research</i> , 2007 , 56, 42-8	10.2	36
171	Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 138-45	15.1	69
170	Resting heart rate in cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 823-30	15.1	722
169	Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1132-7	15.1	69
168	The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2148-55	15.1	41
167	Factor XIII ^A -V34L and factor XIII ^B -H95R gene variants: effects on survival in myocardial infarction patients. <i>Molecular Medicine</i> , 2007 , 13, 112-20	6.2	25
166	Percutaneous coronary injection of bone marrow cells in small experimental animals: small is not too small. <i>Pathology Research and Practice</i> , 2007 , 203, 801-8	3.4	1
165	Sedation with midazolam for electrical cardioversion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007 , 30, 608-11	1.6	12
164	Hibernating myocardium: diagnosis and patient outcomes. <i>Current Problems in Cardiology</i> , 2007 , 32, 375-410	4.1	262
163	Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. <i>European Journal of Pharmacology</i> , 2007 , 577, 1-6	5.3	61

162	Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril ^B prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). <i>American Journal of Cardiology</i> , 2007 , 100, 159-63	3	50
161	Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 423-9	3.9	44
160	Relevance of apoptosis in influencing recovery of hibernating myocardium. <i>European Journal of Heart Failure</i> , 2007 , 9, 377-83	12.3	10
159	ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. <i>Cardiovascular Research</i> , 2007 , 73, 237-46	9.9	123
158	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , 2007 , 93, 1081-6	5.1	44
157	Left bundle branch block as a risk factor for progression to heart failure. <i>European Journal of Heart Failure</i> , 2007 , 9, 7-14	12.3	112
156	Radiofrequency catheter ablation to cure atrial fibrillation: may be a wrong target. <i>Journal of Cardiovascular Medicine</i> , 2007 , 8, 718-9	1.9	0
155	Implantable cardioverter defibrillators: from evidence of trials to clinical practice. <i>Country Review Ukraine</i> , 2007 , 9, 166-173		11
154	Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. <i>American Heart Journal</i> , 2007 , 153, 629-35	4.9	15
153	Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. <i>American Heart Journal</i> , 2007 , 154, 39-45	4.9	14
152	Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. <i>International Journal of Cardiology</i> , 2007 , 121, 57-61	3.2	11
151	Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. <i>European Heart Journal</i> , 2006 , 27, 1070-8	9.5	87
150	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , 2006 , 27, 796-801	9.5	49
149	One heart, two lungs together forever. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 962-3	10.2	4
148	Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. <i>Future Cardiology</i> , 2006 , 2, 17-27	1.3	2
147	Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. <i>Archives of Internal Medicine</i> , 2006 , 166, 659-66		109
146	Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 2800-6	9.4	46
145	Improved detection of left ventricular thrombi and spontaneous echocontrast by tissue harmonic imaging in patients with myocardial infarction. <i>Journal of the American Society of Echocardiography</i> , 2006 , 19, 1373-81	5.8	7

144	Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2178-85	15.1	125
143	Anti-ischæmic effect of ivabradine. <i>Pharmacological Research</i> , 2006 , 53, 435-9	10.2	32
142	Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvALUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. <i>American Heart Journal</i> , 2006 , 152, 860-6	4.9	67
141	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. <i>Peptides</i> , 2006 , 27, 1776-86	3.8	37
140	Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and pReservedPleft ventricular function?. <i>European Heart Journal</i> , 2006 , 27, 2154-7	9.5	11
139	Aldosterone blockade in post-acute myocardial infarction heart failure. <i>Clinical Cardiology</i> , 2006 , 29, 434-8	3.3	4
138	Feasibility of the transeptal approach for fast and unstable left ventricular tachycardia mapping and ablation with a non-contact mapping system. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2006 , 16, 111-6	2.4	9
137	White coats and fingerprints: diagnostic reasoning in medicine and investigative methods of fictional detectives. <i>BMJ, The</i> , 2005 , 331, 1491-4	5.9	20
136	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. <i>Country Review Ukraine</i> , 2005 , 7, K31-K35		1
135	The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. <i>European Heart Journal</i> , 2005 , 26, 1369-78	9.5	105
134	Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. <i>Country Review Ukraine</i> , 2005 , 7, H16-H21		7
133	Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism. <i>Cytokine</i> , 2005 , 30, 236-42	4	6
132	Specific properties and effect of perindopril in controlling the renin-angiotensin system. <i>American Journal of Hypertension</i> , 2005 , 18, 142S-154S	2.3	24
131	Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes. <i>Pharmacological Research</i> , 2005 , 51, 409-17	10.2	21
130	Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 15-29	2.5	50
129	Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 2109-17	27.4	253
128	Atrial fibrillation and recurrent ventricular fibrillation during hypokalemia in Brugada syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005 , 28, 1350-3	1.6	15
127	Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. <i>European Journal of Heart Failure</i> , 2005 , 7, 295-302	12.3	49

126	Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. <i>European Heart Journal</i> , 2005 , 26, 1838-45	9.5	188
125	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). <i>European Heart Journal</i> , 2005 , 26, 215-25	9.5	1076
124	Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. <i>Circulation</i> , 2005 , 111, 863-70	16.7	159
123	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , 2005 , 26, 384-416	9.5	950
122	Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. <i>European Heart Journal</i> , 2005 , 26, 2232-7	9.5	197
121	Expert consensus document on beta-adrenergic receptor blockers. <i>European Heart Journal</i> , 2004 , 25, 1341-62	9.5	365
120	CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. <i>Circulation</i> , 2004 , 110, 1209-12	16.7	322
119	Oxidative stress during myocardial ischaemia and heart failure. <i>Current Pharmaceutical Design</i> , 2004 , 10, 1699-711	3.3	152
118	Assessment of left ventricular volume and function by integration of simplified 3D echocardiography, tissue harmonic imaging and automated extraction of endocardial borders. <i>International Journal of Cardiovascular Imaging</i> , 2004 , 20, 191-202	2.5	7
117	High-dose bolus tirofiban and sirolimus eluting stent versus abciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 225-30	3.9	12
116	Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1033, 79-91	6.5	173
115	TNFalpha in patients with congestive heart failure. <i>Basic Research in Cardiology</i> , 2004 , 99, 12-7	11.8	6
114	The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , 2004 , 25, 1880-90	9.5	394
113	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 1213-1232	1.5	1
112	Improved recognition of dysfunctioning myocardial segments by longitudinal strain rate versus velocity in patients with myocardial infarction. <i>Journal of the American Society of Echocardiography</i> , 2004 , 17, 313-21	5.8	23
111	Effect of nolomirole on monocrotaline-induced heart failure. <i>Pharmacological Research</i> , 2004 , 49, 1-5	10.2	8
110	Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2000-8	15.1	41
109	The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 14-9	15.1	128

108	Arginase pathway in human endothelial cells in pathophysiological conditions. <i>Journal of Molecular and Cellular Cardiology</i> , 2004 , 37, 515-23	5.8	81
107	Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2004 , 37, 939-45	5.8	70
106	Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. <i>Coronary Artery Disease</i> , 2004 , 15, 65-71	1.4	13
105	Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. <i>Circulation</i> , 2003 , 107, 264-70	16.7	57
104	Species-specific modulation of the nitric oxide pathway after acute experimentally induced endotoxemia. <i>Critical Care Medicine</i> , 2003 , 31, 1509-14	1.4	13
103	PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. <i>Cardiovascular Drugs and Therapy</i> , 2003 , 17, 83-91	3.9	20
102	Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure. <i>Basic Research in Cardiology</i> , 2003 , 98, 114-23	11.8	10
101	Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, RC1-4	5.2	3
100	Oxidative stress in cardiovascular disease: myth or fact?. <i>Archives of Biochemistry and Biophysics</i> , 2003 , 420, 217-21	4.1	124
99	Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. <i>Archives of Biochemistry and Biophysics</i> , 2003 , 420, 255-61	4.1	64
98	Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. <i>American Heart Journal</i> , 2003 , 146, E17	4.9	21
97	Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. <i>Circulation</i> , 2003 , 107, 565-70	16.7	643
96	Revascularization of hibernating myocardium: rate of metabolic and functional recovery and occurrence of oxidative stress. <i>European Heart Journal</i> , 2002 , 23, 1877-85	9.5	7
95	A Sample-saving preparation to extract DNA-binding proteins from cardiac and vascular tissues. <i>Laboratory Investigation</i> , 2002 , 82, 667-9	5.9	
94	Metabolic approaches to the treatment of ischemic heart disease: the clinicians perspective. <i>Heart Failure Reviews</i> , 2002 , 7, 187-203	5	66
93	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2002 , 16, 149-60	3.9	96
92	Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. <i>European Heart Journal</i> , 2002 , 23, 967-74	9.5	169
91	Cellular thiols redox status: a switch for NF-kappaB activation during myocardial post-ischaemic reperfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 2002 , 34, 997-1005	5.8	25

90	Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 155-61	15.1	65
89	Future strategies of reverse remodeling prevention of hibernation. <i>Journal of Cardiac Failure</i> , 2002 , 8, S542-8	3.3	0
88	Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. <i>International Journal of Cardiology</i> , 2002 , 86, 77-85	3.2	45
87	Beta-adrenergic receptors and intracellular signalling pathway in stunned and non-ischemic regions of pig myocardium. <i>Basic Research in Cardiology</i> , 2001 , 96, 388-94	11.8	2
86	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. <i>Cardiovascular Drugs and Therapy</i> , 2001 , 15, 529-37	3.9	3
85	Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. <i>British Journal of Pharmacology</i> , 2001 , 133, 145-53	8.6	13
84	The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. <i>American Journal of Cardiology</i> , 2001 , 87, 1058-63	3	192
83	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <i>American Journal of Cardiology</i> , 2001 , 88, 1L-20L	3	164
82	Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. <i>Circulation</i> , 2001 , 104, 253-6	16.7	308
81	Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2001 , 33, 395-403	5.8	36
80	Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. <i>Advances in Experimental Medicine and Biology</i> , 2000 , 482, 351-9	3.6	47
79	New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage. <i>Cardiovascular Research</i> , 2000 , 47, 586-94	9.9	46
78	Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium. <i>European Heart Journal</i> , 2000 , 21, 1358-67	9.5	39
77	Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. <i>Cardiovascular Research</i> , 2000 , 47, 556-66	9.9	25
76	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 569-82	15.1	1782
75	Pro-inflammatory and pro-apoptotic factors in heart failure 2000 , 261-271		
74	Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. <i>European Heart Journal</i> , 1999 , 20, 1503-13	9.5	28
73	Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. <i>Circulation</i> , 1999 , 100, 1983-91	16.7	191

72	High-dose heparin impairs nitric oxide pathway and vasomotion in rats. <i>Circulation</i> , 1999 , 99, 2861-3	16.7	12
71	Endothelial Dysfunction in Congestive Heart Failure: Effects of Carvedilol. <i>Heart Failure Reviews</i> , 1999 , 4, 53-64	5	1
70	Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies. <i>Journal of Heart and Lung Transplantation</i> , 1999 , 18, 478-87	5.8	16
69	Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects. <i>American Heart Journal</i> , 1999 , 138, S61-8	4.9	28
68	Cardioprotection: intermittent ventricular fibrillation and rapid pacing can induce preconditioning in the blood-perfused rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 1999 , 31, 1961-73	5.8	23
67	Role of A2A receptor in the modulation of myocardial reperfusion damage. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, 883-93	3.1	44
66	Hibernating myocardium: Its pathophysiology and clinical role. <i>Molecular and Cellular Biochemistry</i> , 1998 , 186, 195-199	4.2	14
65	Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1998 , 12, 291-9	3.9	59
64	Metabolic derangement in ischemic heart disease and its therapeutic control. <i>American Journal of Cardiology</i> , 1998 , 82, 2K-13K	3	35
63	Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium?. <i>Progress in Cardiovascular Diseases</i> , 1998 , 41, 25-30	8.5	43
62	Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy. <i>Cardiovascular Research</i> , 1998 , 39, 233-41	9.9	35
61	"Myocardial stunning" remaining questions. <i>Cardiovascular Research</i> , 1998 , 38, 549-58	9.9	28
60	Hibernating Myocardium 1998 , 23-31		
59	Hibernating myocardium: Its pathophysiology and clinical role 1998 , 195-199		
58	Effects of Lercanidipine on Fe ²⁺ -Induced Mitochondrial Lipid Peroxidation. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 29, S63-S72	3.1	1
57	Angiotensin converting enzyme inhibitor/calcium antagonist combination. <i>Journal of Hypertension</i> , 1997 , 15, S109-S117	1.9	8
56	The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. <i>Journal of Cardiac Failure</i> , 1997 , 3, 217-24	3.3	31
55	Acute increase of myocardial workload, hemodynamic instability, and myocardial histological changes induced by brain death in the cat. <i>Journal of Surgical Research</i> , 1997 , 68, 7-15	2.5	26

54	Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance?. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 25-34	5.1	11
53	Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). <i>Circulation</i> , 1997 , 96, 3205-14	16.7	112
52	Aorta and skeletal muscle NO synthase expression in experimental heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 1996 , 28, 2241-8	5.8	70
51	Skeletal muscle metabolism in experimental heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 1996 , 28, 2263-73	5.8	13
50	Is stunning an important component of preconditioning?. <i>Journal of Molecular and Cellular Cardiology</i> , 1996 , 28, 2323-31	5.8	7
49	Metabolic and functional consequences of successive no-flow and sustained low-flow ischaemia; a 31P MRS study in rat hearts. <i>Journal of Molecular and Cellular Cardiology</i> , 1996 , 28, 2373-81	5.8	18
48	Continuous versus intermittent warm blood cardioplegia: functional and energetics changes. <i>Annals of Thoracic Surgery</i> , 1996 , 62, 1172-8; discussion 1178-9	2.7	16
47	Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. <i>American Journal of Cardiology</i> , 1996 , 77, 22D-25D	3	11
46	Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection. <i>Cardiovascular Drugs and Therapy</i> , 1996 , 10, 425-37	3.9	7
45	Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia. <i>Molecular and Cellular Biochemistry</i> , 1996 , 160-161, 187-94	4.2	10
44	Metabolic adaptation during a sequence of no-flow and low-flow ischemia. A possible trigger for hibernation. <i>Circulation</i> , 1996 , 94, 2587-96	16.7	48
43	Calcium antagonists and left ventricular dysfunction. <i>American Journal of Cardiology</i> , 1995 , 75, 71E-76E	3	7
42	Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. <i>Circulation</i> , 1995 , 92, 1479-86	16.7	362
41	Calcium and Calcium Channel Regulation in Cardiac Function. <i>Medical Science Symposia Series</i> , 1995 , 57-64		
40	Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 617-26	15.1	314
39	Effect of angiotensin converting enzyme inhibition with quinaprilat on the ischaemic and reperfused myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 1994 , 26, 69-86	5.8	20
38	Plasma levels of atrial natriuretic factor (ANF) and urinary excretion of ANF, arginine vasopressin and catecholamines in children with congenital heart disease: effect of cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 1993 , 7, 533-9	3	14
37	Cardioprotection by nisoldipine: role of timing of administration. <i>European Heart Journal</i> , 1993 , 14, 1258-72	7.2	42

36	Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts. <i>Molecular and Cellular Biochemistry</i> , 1993 , 125, 73-86	4.2	9
35	Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 1992 , 24, 219-32 ^{5,8}	5.8	28
34	Lipid peroxidation during myocardial reperfusion. <i>Molecular and Cellular Biochemistry</i> , 1992 , 111, 49-54	4.2	8
33	Occurrence of oxidative stress during myocardial reperfusion. <i>Molecular and Cellular Biochemistry</i> , 1992 , 111, 61-9	4.2	56
32	Role of timing of administration in the cardioprotective effect of fructose-1,6-bisphosphate. <i>Cardiovascular Drugs and Therapy</i> , 1992 , 6, 209-17	3.9	6
31	Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1992 , 346, 339-44	3.4	3
30	Stunning: Damaging or Protective to the Myocardium? 1992 , 166-179		
29	Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. <i>American Journal of Cardiology</i> , 1991 , 67, 732-6	3	70
28	Stunning: damaging or protective to the myocardium?. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5, 939-45.	3.9	15
27	The occurrence of oxidative stress during reperfusion in experimental animals and men. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5 Suppl 2, 277-87	3.9	36
26	Effects of some L-carnitine derivatives on heart membrane ATPases. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5 Suppl 1, 25-30	3.9	23
25	Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. <i>European Journal of Cardio-thoracic Surgery</i> , 1991 , 5, 205-10 ³		7
24	Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. <i>American Journal of Medicine</i> , 1991 , 91, 95S-105S	2.4	169
23	Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1991 , 17, 208-17	15.1	30
22	The influence of right heart catheterisation on pulmonary arterial pressure in chronic heart failure: relationship to neuroendocrinal changes. <i>International Journal of Cardiology</i> , 1991 , 33, 365-76	3.2	5
21	Role of oxygen free radicals in ischemic and reperfused myocardium. <i>American Journal of Clinical Nutrition</i> , 1991 , 53, 215S-222S	7	66
20	Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1990 , 99, 919-928	1.5	31
19	Occurrence of oxidative stress during reperfusion of the human heart. <i>Circulation</i> , 1990 , 81, 201-11	16.7	247

18	Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. <i>International Journal of Cardiology</i> , 1990 , 28, 341-6	3.2	19
17	Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil. <i>Cardiovascular Drugs and Therapy</i> , 1989 , 3, 403-12	3.9	18
16	Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration. <i>Basic Research in Cardiology</i> , 1989 , 84, 606-22	11.8	31
15	Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage. <i>Molecular and Cellular Biochemistry</i> , 1989 , 88, 161-8	4.2	30
14	Hemodynamic, hormonal, and renal effects of atrial natriuretic peptide in untreated congestive cardiac failure. <i>American Heart Journal</i> , 1989 , 118, 500-5	4.9	15
13	Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. <i>British Journal of Pharmacology</i> , 1989 , 98, 678-84	8.6	24
12	Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. <i>Cardiovascular Research</i> , 1989 , 23, 674-82	9.9	41
11	Effect of lipid peroxidation on heart mitochondria oxygen consuming and calcium transporting capacities. <i>Molecular and Cellular Biochemistry</i> , 1988 , 81, 131-5	4.2	23
10	Protective effect of a prostacyclin-mimetic on the ischaemic-reperfused rabbit myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 1988 , 20, 1095-106	5.8	24
9	Long-Lasting Protective Effect of Anipamil, a New Calcium Entry Blocker, against Myocardial Ischemia and Reperfusion Damage. <i>Annals of the New York Academy of Sciences</i> , 1988 , 522, 522-524	6.5	1
8	Effects of verapamil and nifedipine on rate of left ventricular relaxation in coronary arterial disease patients. <i>International Journal of Cardiology</i> , 1987 , 14, 333-41	3.2	16
7	Effects of calcium entry blockers not connected with calcium channels inhibition. <i>General Pharmacology</i> , 1987 , 18, 431-6		14
6	Myocardial recovery during post-ischaemic reperfusion: effects of nifedipine, calcium and magnesium. <i>Journal of Molecular and Cellular Cardiology</i> , 1986 , 18, 487-98	5.8	127
5	Changes in the cardiac glutathione status after ischemia and reperfusion. <i>Experientia</i> , 1985 , 41, 42-3		104
4	Oxygen-mediated myocardial damage during ischaemia and reperfusion: role of the cellular defences against oxygen toxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 1985 , 17, 937-45	5.8	326
3	Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. <i>American Journal of Cardiology</i> , 1980 , 46, 242-8	3	429
2	Lactate production after left ventricular angiography in coronary artery disease. <i>American Heart Journal</i> , 1978 , 96, 835-6	4.9	2
1	Prolonged protective effect of propranolol on hypoxic heart muscle. <i>American Journal of Cardiology</i> , 1978 , 42, 217-25	3	30

